CTMC is a clinical cancer center that integrates advanced biologics manufacturing with data-rich clinical trials to develop and commercialize cell therapies for cancer treatment. By leveraging a purpose-built cGMP cleanroom and collaboration with MD Anderson, CTMC accelerates the transition of novel therapies from research to patient care, aiming for effective single-dose cures.
Funding
Funding not disclosed
Founders
Product
Problem
The development and commercialization of cell therapies for cancer treatment face challenges in efficiently translating research breakthroughs into patient care. Traditional approaches often lack seamless integration between advanced biologics manufacturing, data-rich clinical trials, and the logistical complexities of cell therapy production and delivery.
Solution
CTMC integrates advanced biologics manufacturing with data-rich clinical trials to accelerate the development and commercialization of cell therapies for cancer treatment. By combining a purpose-built cGMP cleanroom with access to a leading cancer center's research capabilities, CTMC facilitates the transition of novel therapies from the lab to the clinic. This integrated approach coordinates cell therapy manufacturing, infusion, patient care, and clinical correlate analysis, providing novel therapies the best chance to demonstrate their potential in a patient-efficient manner. CTMC leverages cloud-based, digital-first electronic systems to manage the logistics of cell therapy manufacturing and delivery.
Target Audience
CTMC serves academic researchers, biotech companies, and cancer centers seeking to develop and commercialize novel cell therapies for cancer treatment.
Features
- Purpose-built 60,000 sq. ft. cell therapy development and industrial-grade cGMP cleanroom space
- Integration of biologics manufacturing technology with clinical cancer center resources
- Cloud-based, digital-first electronic systems for managing cell therapy manufacturing logistics
- Coordination of cell therapy manufacturing, infusion, patient care, and clinical correlate analysis
- Focus on single-dose cures for cancer
- Close relationships with manufacturing technology development engineers and key opinion leaders